Fosamprenavir sodium  (Synonyms: Amprenavir phosphate sodium; GW 433908 sodium)

Fosamprenavir sodium is an orally active inhibitor targeting HIV-1 protease and is a prodrug of Amprenavir (HY-17430). Fosamprenavir sodium is hydrolyzed into Amprenavir (VX-478) by cell phosphatases in the intestinal epithelium. Amprenavir binds to the active site of HIV-1 protease, preventing the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the formation of mature infectious virus particles and exerting anti-HIV-1 infection activity. Fosamprenavir sodium can be used for the study of human immunodeficiency virus (HIV-1) infection^[1][2].

Amprenavir, the active form of Fosamprenavir sodium, can bind to and inhibit the activity of pepsin in vitro with an IC₅₀ of 3.56 μM^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Fosamprenavir (20 mg/kg/day; gavage; daily; 4 weeks) sodium protects against pepsin-mediated laryngeal injury (e.g., reactive epithelium, increased intraepithelial inflammatory cells, and apoptosis) in the Jackson A/J mouse model of laryngeal reflux^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

629.57

C₂₅H₃₄N₃Na₂O₉PS

226700-80-7

O=C(O[C@H]1CCOC1)N[C@@H](CC2=CC=CC=C2)[C@H](OP(O[Na])(O[Na])=O)CN(CC(C)C)S(=O)(C3=CC=C(C=C3)N)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Hester EK, et al. Fosamprenavir: drug development for adherence. Ann Pharmacother. 2006 Jul-Aug;40(7-8):1301-10.  [Content Brief]

  [2]. Johnston N, et al. Oral and Inhaled Fosamprenavir Reverses Pepsin-Induced Damage in a Laryngopharyngeal Reflux Mouse Model. Laryngoscope. 2023 Jan;133 Suppl 1(Suppl 1):S1-S11.  [Content Brief]